ELEVIDYS
Live / Registered — Registered (as of 25 Apr 2023)
What this means for you
Registered since 25 Apr 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88886693
- Registration number
- 7037471
- Mark type
- Stylized text
- Filed
- 24 Apr 2020
- Published for opposition
- 14 Jul 2020
- Registered
- 25 Apr 2023
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapies for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases
Owner
- Sarepta Therapeutics, Inc., Cambridge, MA, US
- Sarepta Therapeutics, Inc., Cambridge, MA, US
- Sarepta Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 25 Apr 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 25 Apr 2023 — REGISTERED-PRINCIPAL REGISTER
- 23 Mar 2023 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 22 Mar 2023 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 20 Mar 2023 — STATEMENT OF USE PROCESSING COMPLETE
- 14 Mar 2023 — USE AMENDMENT FILED
- 14 Mar 2023 — TEAS STATEMENT OF USE RECEIVED
- 07 Mar 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 Mar 2023 — SOU EXTENSION 5 GRANTED
- 17 Feb 2023 — SOU EXTENSION 5 FILED
- 03 Mar 2023 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 17 Feb 2023 — SOU TEAS EXTENSION RECEIVED
- 26 Aug 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Aug 2022 — SOU EXTENSION 4 GRANTED
- 24 Aug 2022 — SOU EXTENSION 4 FILED